227 related articles for article (PubMed ID: 22358377)
1. [Value of positron emission tomography in urological neoplasms: more form than substance?].
Müller J; Schrader M; Schrader AJ; Höpfner M; Zengerling F
Urologe A; 2012 Mar; 51(3):331-40. PubMed ID: 22358377
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
[TBL] [Abstract][Full Text] [Related]
3. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic relevance of choline-PET / CT in patients with prostate cancer].
Zengerling F; Schrader AJ; Schrader M; Jentzmik F
Aktuelle Urol; 2012 Jan; 43(1):49-54. PubMed ID: 21769763
[TBL] [Abstract][Full Text] [Related]
5. Novel imaging modalities for lymph node imaging in urologic oncology.
Chernyak V
Urol Clin North Am; 2011 Nov; 38(4):471-81, vii. PubMed ID: 22045178
[TBL] [Abstract][Full Text] [Related]
6. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy.
Rabalais AG; Walvekar R; Nuss D; McWhorter A; Wood C; Fields R; Mercante DE; Pou AM
Laryngoscope; 2009 Jun; 119(6):1120-4. PubMed ID: 19358193
[TBL] [Abstract][Full Text] [Related]
8. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
9. [Post-therapeutic imaging strategies and follow-up in head and neck malignant tumours].
Aschenbach R; Esser D
HNO; 2010 Aug; 58(8):749-55. PubMed ID: 20640391
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer.
Subramaniam RM; Truong M; Peller P; Sakai O; Mercier G
AJNR Am J Neuroradiol; 2010 Apr; 31(4):598-604. PubMed ID: 19910448
[TBL] [Abstract][Full Text] [Related]
11. Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2.
Alt CD; Brocker KA; Eichbaum M; Sohn C; Arnegger FU; Kauczor HU; Hallscheidt P
Strahlenther Onkol; 2011 Nov; 187(11):705-14. PubMed ID: 22037656
[TBL] [Abstract][Full Text] [Related]
12. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
[TBL] [Abstract][Full Text] [Related]
14. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
15. Update on advances in molecular PET in urological oncology.
Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
[TBL] [Abstract][Full Text] [Related]
16. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
[TBL] [Abstract][Full Text] [Related]
17. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
19. Role of the standardized uptake value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in detecting the primary tumor and lymph node metastasis in colorectal cancers.
Uchiyama S; Haruyama Y; Asada T; Hotokezaka M; Nagamachi S; Chijiiwa K
Surg Today; 2012 Oct; 42(10):956-61. PubMed ID: 22711186
[TBL] [Abstract][Full Text] [Related]
20.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
